Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DURABOLIN vs ORTHO TRI-CYCLEN LO
Head-to-head clinical comparison of therapeutic indices and safety profiles.
DURABOLIN (nandrolone phenpropionate) is an anabolic steroid that binds to androgen receptors, increasing protein synthesis and nitrogen retention, promoting muscle growth and bone density. It also stimulates erythropoietin production, increasing red blood cell mass.
Combination estrogen (ethinyl estradiol) and progestin (norgestimate) oral contraceptive. Suppresses gonadotropin release, inhibiting ovulation; increases cervical mucus viscosity, impeding sperm penetration; alters endometrial lining, reducing implantation likelihood.
Adjunctive therapy to promote weight gain after severe illness, surgery, or trauma,Osteoporosis (off-label),Anemia of renal failure (off-label),HIV/AIDS wasting syndrome (off-label)
Prevention of pregnancy,Acne vulgaris (for women aged ≥15 who desire contraception)
100-200 mg intramuscularly every 1-2 weeks for testosterone replacement; for wasting syndromes, 50-100 mg intramuscularly weekly.
One tablet daily orally for 21 days, followed by 7 placebo tablets. Each active tablet contains 0.025 mg ethinyl estradiol and 0.18 mg norelgestromin (days 1-7), 0.215 mg norelgestromin (days 8-14), 0.25 mg norelgestromin (days 15-21).
Terminal elimination half-life: 4-6 days (intramuscular depot), reflecting slow release from injection site and enterohepatic recirculation; clinical steady-state achieved after 3-6 weeks.
Norelgestromin: 15-20 hours; Ethinyl estradiol: 13-16 hours. Steady-state achieved within 7 days.
Hepatic metabolism via reduction and conjugation; primarily excreted in urine as metabolites (e.g., 19-norandrosterone and 19-noretiocholanolone).
No specific guidelines; use caution in severe impairment (Cr Cl <30 m L/min) due to fluid retention and potential edema.
No dose adjustment recommended for mild to moderate renal impairment. Not studied in severe renal impairment (GFR <30 m L/min); use contraindicated in patients with renal disease.
Anabolic steroids may cause peliosis hepatis, liver cell tumors, and blood lipid changes associated with increased cardiovascular risk. Prolonged use can lead to azoospermia, oligospermia, and impotence. Not approved for enhancing athletic performance.
DURABOLIN (nandrolone) is contraindicated in pregnancy. Androgens can cause virilization of the female fetus. First trimester exposure risks clitoromegaly, labial fusion, and urogenital sinus abnormalities. Second and third trimester exposure may lead to clitoromegaly and advanced bone age. Fetal growth restriction and preterm birth are also reported.
Pregnancy category X. Contraindicated in pregnancy. First trimester: Increased risk of cardiovascular defects, neural tube defects, and oral clefts. Second and third trimesters: Not indicated; no specific fetal risks documented due to contraindication.
Durabolin (nandrolone phenylpropionate) is an injectable anabolic steroid with a shorter ester than nandrolone decanoate, allowing for faster onset and offset. Monitor liver function tests and lipid profiles, as it can cause HDL suppression and LDL elevation. Use with caution in patients with pre-existing cardiac, hepatic, or renal disease. Suppresses endogenous testosterone; consider testosterone replacement during and after therapy. Detectable on doping tests for up to 18 months in athletes; educate accordingly.
Lower estrogen dose (0.025 mg ethinyl estradiol) may cause more breakthrough bleeding, especially in the first few cycles. Counsel patients that unscheduled bleeding is common and usually improves after 3-6 months. The 91-day extended regimen (7 days placebo) reduces number of withdrawal bleeds but may increase spotting. Contraceptive efficacy may be reduced in patients with BMI > 30; consider alternative methods. Monitor blood pressure after starting, as estrogen can elevate BP. Absolute contraindication in migraine with aura, history of thromboembolism, or smoking >35 years old.
No interactions on record
No interactions on record
DURABOLIN and ORTHO TRI-CYCLEN LO are distinct pharmacological agents. DURABOLIN belongs to the Anabolic Androgenic Steroid class and is primarily used for Adjunctive therapy to promote weight gain after severe illness, surgery, or traumaOsteoporosis (off-label)Anemia of renal failure (off-label)HIV/AIDS wasting syndrome (off-label). ORTHO TRI-CYCLEN LO belongs to the Hormonal Contraceptive class and is primarily used for Prevention of pregnancyAcne vulgaris (for women aged ≥15 who desire contraception). Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. DURABOLIN carries a safety status of Category C, whereas ORTHO TRI-CYCLEN LO safety is classified as Category C. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Metabolized primarily via CYP3A4 oxidation; ethinyl estradiol undergoes phase II conjugation (glucuronidation and sulfation).
Primarily renal: 90% as metabolites (glucuronide and sulfate conjugates), 10% unchanged; negligible biliary/fecal elimination.
Renal (∼40% as metabolites, <10% unchanged) and fecal (∼30% as metabolites); conjugated metabolites excreted in bile and undergo enterohepatic circulation.
85-95% bound to sex hormone-binding globulin (SHBG) and albumin; high affinity for SHBG, reducing free active fraction.
Norelgestromin: 99%, primarily to albumin; Ethinyl estradiol: 97-98%, primarily to albumin and sex hormone-binding globulin (SHBG).
4-6 L/kg, indicating extensive tissue distribution, particularly to skeletal muscle, bone, and prostate.
Norelgestromin: 2.5-3.5 L/kg; Ethinyl estradiol: 2-4 L/kg; extensive tissue distribution.
Intramuscular: ~100% (depot formulation); oral: negligible (<1% due to first-pass hepatic metabolism).
Oral: Norelgestromin ~100% (after first-pass conversion from norgestimate); Ethinyl estradiol ~45% (due to first-pass metabolism).
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use due to risk of cholestasis and hepatotoxicity.
Contraindicated in Child-Pugh Class B or C (moderate to severe hepatic impairment). Not studied in Child-Pugh Class A; use caution.
Not recommended in children due to premature epiphyseal closure and potential virilization; limited data, use only under expert supervision for delayed growth.
No specific weight-based dosing; use only after menarche. Dose same as adult: one active tablet daily for 21 days then 7 placebo. Safety and efficacy established in females of reproductive age.
Initiate at lowest effective dose (e.g., 50 mg IM every 2 weeks) due to increased risk of prostatic hypertrophy, fluid retention, and polycythemia.
Not indicated for use in postmenopausal women; no geriatric dosing studies conducted.
Cigarette smoking increases risk of serious cardiovascular events (e.g., thromboembolism, stroke, myocardial infarction). Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use combination oral contraceptives.
Risk of hepatic dysfunction, peliosis hepatis, hepatocellular carcinoma, hyperlipidemia, cardiovascular disease, edema, hypertension, glucose intolerance, premature closure of epiphyseal growth plates in children, virilization in women, and prostate hypertrophy in men. Monitor liver function, lipid profile, and hematocrit. Use with caution in patients with cardiac, renal, or hepatic disease.
Known hypersensitivity to nandrolone or any component, pregnant or breastfeeding women, men with carcinoma of the breast or prostate, nephrotic syndrome, hypercalcemia, severe hepatic dysfunction, and patients with a history of myocardial infarction or coronary artery disease.
No specific food interactions reported. However, maintain a balanced diet low in saturated fats and sodium to mitigate adverse lipid and cardiovascular effects. Avoid excessive alcohol consumption due to hepatotoxicity risk.
No known food interactions. Grapefruit juice may increase estrogen levels, but effect is not clinically significant with low-dose pills. Maintain a consistent diet to avoid gastrointestinal disturbances that could affect absorption.
Nandrolone is excreted into breast milk. The milk-to-plasma ratio is not established. Androgens may suppress lactation and cause virilization in the nursing infant. Use during breastfeeding is contraindicated.
Small amounts of estrogen and progestin are excreted in breast milk (M/P ratio not available). May reduce milk production and quality. Not recommended during breastfeeding.
No dosing adjustments are applicable as DURABOLIN is contraindicated in pregnancy. No pharmacokinetic data in pregnancy to guide dose modification.
Contraindicated in pregnancy; no dosing adjustments applicable. Discontinue immediately if pregnancy occurs.
This medication is for intramuscular injection only; do not inject intravenously.,Report signs of liver problems (jaundice, dark urine, abdominal pain) or heart issues (chest pain, shortness of breath) immediately.,May cause changes in libido, acne, hair growth, or voice deepening; these may be irreversible.,Regular blood tests are required to monitor liver function, cholesterol, and blood count.,Do not share needles; proper disposal of used syringes is mandatory.,Avoid use during pregnancy and breastfeeding.,May interact with blood thinners (e.g., warfarin) and oral antidiabetics; advise dose adjustments.
Take one pill daily at the same time each day, even if you do not have intercourse regularly.,If you miss a pill, refer to the package insert for specific instructions based on how many pills you missed and the week of the cycle.,Breakthrough bleeding or spotting is common in the first 3-6 months; contact your healthcare provider if bleeding is heavy or prolonged.,This product does not protect against HIV or other sexually transmitted infections; use condoms for infection prevention.,Tell your healthcare provider if you start smoking, as smoking increases the risk of serious cardiovascular side effects.,Seek emergency medical attention if you experience sudden chest pain, shortness of breath, leg pain or swelling, severe headache, or vision changes.,Store at room temperature (20-25°C); keep in original blister pack until use.,If you have vomiting or diarrhea for more than 24 hours, use backup contraception until you have taken 7 consecutive active pills.